| # | Title | Journal | Year | Citations |
|---|
| 1 | The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints | Molecular Pharmacology | 2003 | 2,525 |
| 2 | Determination and characterization of a cannabinoid receptor in rat brain | Molecular Pharmacology | 1988 | 1,611 |
| 3 | SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7 | Molecular Pharmacology | 2002 | 1,488 |
| 4 | Hypoxia-Inducible Factor-1 (HIF-1) | Molecular Pharmacology | 2006 | 1,399 |
| 5 | The characterization of two specific drug binding sites on human serum albumin | Molecular Pharmacology | 1975 | 1,286 |
| 6 | Further characterization of specific drug binding sites on human serum albumin | Molecular Pharmacology | 1976 | 1,148 |
| 7 | Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol | Molecular Pharmacology | 1979 | 1,020 |
| 8 | Spectral studies of drug interaction with hepatic microsomal cytochrome | Molecular Pharmacology | 1967 | 904 |
| 9 | Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one | Molecular Pharmacology | 1995 | 881 |
| 10 | [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role | Molecular Pharmacology | 1982 | 878 |
| 11 | Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones | Molecular Pharmacology | 1978 | 856 |
| 12 | G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? | Molecular Pharmacology | 2018 | 825 |
| 13 | The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide | Molecular Pharmacology | 2005 | 804 |
| 14 | Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases | Molecular Pharmacology | 2000 | 746 |
| 15 | Differential Response of Estrogen Receptor α and Estrogen Receptor β to Partial Estrogen Agonists/Antagonists | Molecular Pharmacology | 1998 | 730 |
| 16 | Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro | Molecular Pharmacology | 1978 | 706 |
| 17 | Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes | Molecular Pharmacology | 1986 | 702 |
| 18 | Cloning and Functional Expression of the Human Histamine H3Receptor | Molecular Pharmacology | 1999 | 697 |
| 19 | Neuroprotection against Oxidative Stress by Estrogens: Structure-Activity Relationship | Molecular Pharmacology | 1997 | 694 |
| 20 | Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors | Molecular Pharmacology | 1993 | 688 |
| 21 | The effect of adenosine and adenine nucleotides on the cyclic adenosine 3', 5'-phosphate content of guinea pig cerebral cortex slices | Molecular Pharmacology | 1970 | 674 |
| 22 | A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment | Molecular Pharmacology | 1992 | 669 |
| 23 | Molecular cloning and functional expression of a mu-opioid receptor from rat brain | Molecular Pharmacology | 1993 | 667 |
| 24 | Altered Brain Serotonin Homeostasis and Locomotor Insensitivity to 3,4-Methylenedioxymethamphetamine (“Ecstasy”) in Serotonin Transporter-Deficient Mice | Molecular Pharmacology | 1998 | 659 |
| 25 | Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines | Molecular Pharmacology | 1994 | 646 |
| 26 | Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification | Molecular Pharmacology | 2002 | 614 |
| 27 | The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation ofCYP3A4by Rifampicin through a Distal Enhancer Module | Molecular Pharmacology | 1999 | 607 |
| 28 | Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes | Molecular Pharmacology | 2009 | 601 |
| 29 | The Cannabinoid CB1Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells | Molecular Pharmacology | 2003 | 589 |
| 30 | Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542 | Molecular Pharmacology | 2002 | 582 |
| 31 | Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors | Molecular Pharmacology | 1995 | 576 |
| 32 | Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor | Molecular Pharmacology | 2001 | 553 |
| 33 | Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese | Molecular Pharmacology | 1994 | 547 |
| 34 | dl-threo-β-Benzyloxyaspartate, A Potent Blocker of Excitatory Amino Acid Transporters | Molecular Pharmacology | 1998 | 538 |
| 35 | Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors | Molecular Pharmacology | 2006 | 527 |
| 36 | (−)-Epigallocatechin-3-gallate Blocks the Induction of Nitric Oxide Synthase by Down-Regulating Lipopolysaccharide-Induced Activity of Transcription Factor Nuclear Factor-κB | Molecular Pharmacology | 1997 | 524 |
| 37 | Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain | Molecular Pharmacology | 2001 | 523 |
| 38 | The Repertoire of G-Protein–Coupled Receptors in Fully Sequenced Genomes | Molecular Pharmacology | 2005 | 518 |
| 39 | Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells | Molecular Pharmacology | 1989 | 516 |
| 40 | Is Cisplatin-Induced Cell Death Always Produced by Apoptosis? | Molecular Pharmacology | 2001 | 501 |
| 41 | Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells | Molecular Pharmacology | 1999 | 501 |
| 42 | Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation | Molecular Pharmacology | 2006 | 494 |
| 43 | Mechanisms of Release of Nucleotides and Integration of Their Action as P2X- and P2Y-Receptor Activating Molecules | Molecular Pharmacology | 2003 | 488 |
| 44 | Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor Stimulus | Molecular Pharmacology | 1998 | 484 |
| 45 | Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways | Molecular Pharmacology | 2007 | 480 |
| 46 | Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides | Molecular Pharmacology | 1992 | 474 |
| 47 | Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes | Molecular Pharmacology | 1982 | 473 |
| 48 | Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors | Molecular Pharmacology | 1994 | 472 |
| 49 | Identification and Characterization of Human Organic Anion Transporter 3 Expressing Predominantly in the Kidney | Molecular Pharmacology | 2001 | 470 |
| 50 | TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules | Molecular Pharmacology | 2011 | 466 |
